The latest round of testing for a new Alzheimer's drug didn't produce the results researchers hoped for, but a small number of patients did see some benefit from the medication.
No email address was supplied by
To complete your registration on this site, please supply an address.
Please confirm or modify the email address to which you will have subscription offers sent.
For a more personalized experience, please supply the following optional information.